Urology Medical News about Nonseminoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group
Urologic Oncology: Seminars and Original Investigations, 06/11/09

Bamias A et al. - The authors report the outcome and safety of a risk-adapted strategy by the Hellenic Cooperative Oncology Group. Two cycles of bleomycin/etoposide/cisplatin is an effective and safe form of adjuvant therapy in high-risk stage I NSGCT.

<< Previous
Andrology: Potential for diagnostic errors in men taking statins

Next >>
Testicular cancer: RPLND an effective first-line alternative to...